Cure My Disease

Don't miss your cure!

 Log in / Sign up

Which talc method works best for a leaky lung?

NCT ID NCT07167992

Symptom relief Sponsor: University of Health Sciences Lahore Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at two methods of giving talc to treat fluid buildup or collapsed lung. About 160 people aged 12 and older will get either talc mixed with liquid or talc sprayed as a powder. The goal is to see which method works better, causes fewer side effects, and leads to a shorter hospital stay.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 160 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Feb 2026

An estimate. Start dates often move.

Expected to finish

Mar 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

12 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * patients aged 12 years and older. * Diagnosed with malignant pleural effusions or pneumothoraces. * ECOG performance status of 0-2. * Life expectancy of at least 3 months. * Ability to provide informed consent. * No contraindications to general anesthesia or conscious sedation. Exclusion Criteria: * Patients younger than 12 years old * Female patients who are pregnant or lactating * Patients with encysted or septated pleural effusions and pneumothoraces * Patients presenting with respiratory failure * Patients complaining of dyspnea in spite of complete evacuation of pleural effusion or pneumothorax. * Patients with evident chest infection with clinical or laboratory signs suggestive of parapneumonic effusions.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Pleural effusion, malignant are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

familial spontaneous pneumothorax Pleural Effusion, Malignant pneumothorax

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Pleural effusion, malignant Pleurodesis Pneumothorax spontaneous primary Pneumothorax spontaneous secondary

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Services Institute of Medical Sciences (SIMS), Services Hospital Lahore

    Lahore, Punjab Province, 54000, Pakistan

More trials for these conditions

Other studies related to the condition(s) this trial covers.